Skip to main content
SleepCited

Restless Legs Syndrome: Neurochemistry and Therapy.

David Anguizola, Alba Garcia Aragón, Brian Moncada, Diego Garcia-Borreguero
Review Seminars in neurology 2025
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D40068886'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Review
Population
Patients with restless legs syndrome
Intervention
Restless Legs Syndrome: Neurochemistry and Therapy. None
Comparateur
None
Critère de jugement principal
None
Direction de l'effet
Mixed
Risque de biais
Unclear

Abstract

Restless legs syndrome (RLS) is a complex sensorimotor disorder characterized by disturbances in key neurochemical pathways, including dopaminergic, glutamatergic, and adenosinergic systems. This review provides an overview of the current knowledge on RLS, including its clinical features and diagnosis, pathophysiology, and treatment (non-pharmacological and pharmacological). We examine the association between RLS and neurological disorders, genetic predispositions, and brain iron deficiency. Emerging therapies targeting glutamate and adenosine receptors, alongside established dopamine agonists and α2δ ligands, offer promising avenues for treatment.

Used In Evidence Reviews

Similar Papers